Comparison between chemoembolization combined with radiotherapy and chemoembolization alone for large hepatocellular carcinoma

Table 1 Clinical features and therapeutic modalities in two groups

		TACE group cases (%)	TACE plus irradiation group cases (%)	P value
Sex	Male	75 (84.3)	68 (89.5)
	Female	14 (15.7)	8 (10.5)	0.327
Age	< 60 years	66 (74.2)	57 (75.0)
	≥ 60 years	23 (25.8)	19 (25.0)	0.901
AFP	< 400 ng/ml	45 (50.6)	42 (55.3)
	≥ 400 ng/ml	44 (49.4)	34 (44.7)	0.547
No. of lesions	Solitary	59 (66.3)	51 (67.1)
	Multiple	30 (33.7)	25 (32.9)	0.912
Tumor	1 lobe	72 (81.9)	52 (68.4)
extensiona	2 lobe	17 (19.1)	24 (31.6)	0.064
Tumor size	5-10 cm	51 (57.3)	47 (61.8)
	> 10 cm	38 (42.7)	29 (38.2)	0.554
Portal	Absent	67 (75.3)	62 (81.6)
thrombosis	Present	22 (24.7)	14 (18.4)	0.329
Child grade	A	74 (83.2)	63 (82.9)
	B	15 (16.8)	13 (17.1)	0.996
Okuda stage	I	24 (27.0)	29 (38.2)
	II	65 (73.0)	46 (60.5)
	III		1 (1.3)	0.155
TACE times	1	27 (30.3)	27 (35.5)
	2	42 (47.2)	28 (36.8)
	3	15 (16.9)	11 (14.5)
	4	5 (5.6)	10 (13.2)	0.253
Spongostan use	No	48 (53.9)	44 (57.9)
	Yes	41 (46.1)	32 (42.1)	0.610

^aHepatic lobes were classified as two lobes: right lobe and left lobe.

Table 2 Multivariate analysis of major prognostic factors by the Cox proportional hazards model

Variabes	Regression coefficient	Hazard ratio	P value
Tumor extension	0.8708	2.3888	0.0016
Child grade	0.5685	1.7655	0.0200
Irradiation or not	-0.7256	0.4840	0.0002